Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle

Metabolic syndrome (MetS) doubles the risk of adverse cardiovascular events. Glucagon-like peptide 1 (GLP-1) receptor agonists induce weight loss, increase insulin secretion, and improve glucose tolerance. Studies in healthy animals suggest cardioprotective properties of GLP-1 receptor agonists, per...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes
Autors principals: Dineen, Stacey L., McKenney, Mikaela L., Bell, Lauren N., Fullenkamp, Allison M., Schultz, Kyle A., Alloosh, Mouhamad, Chalasani, Naga, Sturek, Michael
Format: Artigo
Idioma:Inglês
Publicat: American Diabetes Association 2015
Matèries:
Pharmacology and Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4542436/
https://ncbi.nlm.nih.gov/pubmed/25845661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db14-1790
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars